Skip to main content
Top
Published in: Current Diabetes Reports 6/2014

01-06-2014 | Treatment of Type 1 Diabetes (JC Florez, Section Editor)

Reassessment of Insulin Dosing Guidelines in Continuous Subcutaneous Insulin Infusion Treated Type 1 Diabetes

Author: Allen Bennett King

Published in: Current Diabetes Reports | Issue 6/2014

Login to get access

Abstract

It is a daunting task to initiate or evaluate continuous subcutaneous insulin infusion, pump, dosing in a patient with type 1 diabetes. Choosing a low dose may lead to hyperglycemia or, too high, hypoglycemia. Mathematical dosing guidelines were used with the first human insulin injection in 1922. Since that time, they have been enlarged and modified. The current widely published guidelines were developed from retrospective evaluations of pump-downloads in patients without specified diet conditions or timed glucose testing. When diet is controlled and glucose testing is timed to evaluate post-meal excursions and during sleep, recent prospective studies found that these current dosing recommendations for basal insulin were too high and for bolus insulin too low. Further, simple mathematical interrelationships were published that kept the right proportions between the bolus dosing factors and the basal dose.
Literature
1.
go back to reference Bliss M. The Discovery of Insulin. Chicago: University of Chicago Press; 1982.CrossRef Bliss M. The Discovery of Insulin. Chicago: University of Chicago Press; 1982.CrossRef
3.•
go back to reference King AB, Clark D, Wolfe GW. The contribution of the dawn phenomenon to the fasting and post-breakfast hyperglycemia in type 1 diabetes treated with once-nightly glargine. Endocr Pract. 2012;18:558–62. Review of the effect of the dawn phenomenon in basal insulin dosing.PubMedCrossRef King AB, Clark D, Wolfe GW. The contribution of the dawn phenomenon to the fasting and post-breakfast hyperglycemia in type 1 diabetes treated with once-nightly glargine. Endocr Pract. 2012;18:558–62. Review of the effect of the dawn phenomenon in basal insulin dosing.PubMedCrossRef
4.•
go back to reference Heinemann L, Nosek L, Kapitza C, Schweitzer MA, Krinelke L. The time until a change in metabolic effect is induced in patients with type 1 diabetes. Diabetes Care. 2009;32:1437–9. Reminder of the delay action of basal rate change in pump-treated type 1 diabetes.PubMedCentralPubMedCrossRef Heinemann L, Nosek L, Kapitza C, Schweitzer MA, Krinelke L. The time until a change in metabolic effect is induced in patients with type 1 diabetes. Diabetes Care. 2009;32:1437–9. Reminder of the delay action of basal rate change in pump-treated type 1 diabetes.PubMedCentralPubMedCrossRef
5.
go back to reference King AB, Armstrong D. A prospective evaluation of insulin dosing recommendations in patients with type 1 diabetes at near normal glucose control: basal dosing. J Diabetes Sci Technol. 2007;1:36–41.PubMedCentralPubMedCrossRef King AB, Armstrong D. A prospective evaluation of insulin dosing recommendations in patients with type 1 diabetes at near normal glucose control: basal dosing. J Diabetes Sci Technol. 2007;1:36–41.PubMedCentralPubMedCrossRef
6.
go back to reference Wolpert HA, Atakov-Castillo A, Smith SA, Steil GM. Dietary fat acutely increases glucose concentrations and insulin requirements in patients with type 1 diabetes: Implications for carbohydrate-based bolus dose calculation and intensive diabetes management. Diabetes Care. 2013;36:810–6.PubMedCentralPubMedCrossRef Wolpert HA, Atakov-Castillo A, Smith SA, Steil GM. Dietary fat acutely increases glucose concentrations and insulin requirements in patients with type 1 diabetes: Implications for carbohydrate-based bolus dose calculation and intensive diabetes management. Diabetes Care. 2013;36:810–6.PubMedCentralPubMedCrossRef
7.
go back to reference Pankowska E, Blazik M, Groele L. Does the fat-protein meal increase postprandial glucose level in type 1 diabetes patients on insulin pump: the conclusion of a randomized study. Diabetes Technol Ther. 2012;14:16–22.PubMedCrossRef Pankowska E, Blazik M, Groele L. Does the fat-protein meal increase postprandial glucose level in type 1 diabetes patients on insulin pump: the conclusion of a randomized study. Diabetes Technol Ther. 2012;14:16–22.PubMedCrossRef
8.
go back to reference Standards of medical care in diabetes-2014. Diabetes Care. 2014;37(Suppl 1):s14–67. Standards of medical care in diabetes-2014. Diabetes Care. 2014;37(Suppl 1):s14–67.
9.
go back to reference Handelsman Y, Mechanick JI, Blonde L, et al. American association of clinical endocrinologists medical guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract. 2011;17 Suppl 2:1–53.PubMedCrossRef Handelsman Y, Mechanick JI, Blonde L, et al. American association of clinical endocrinologists medical guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract. 2011;17 Suppl 2:1–53.PubMedCrossRef
10.
go back to reference DeWitt DE, Hirsch IB. Outpatient insulin therapy in type1 and type 2 diabetes. JAMA. 2003;289:2254–64.PubMedCrossRef DeWitt DE, Hirsch IB. Outpatient insulin therapy in type1 and type 2 diabetes. JAMA. 2003;289:2254–64.PubMedCrossRef
11.
go back to reference Bode BW. Insulin pump therapy in Therapy for Diabetes Mellitus and related disorders, Fourth edition. In: Lebovitz HE, editor. American Diabetes Association; 2004. Bode BW. Insulin pump therapy in Therapy for Diabetes Mellitus and related disorders, Fourth edition. In: Lebovitz HE, editor. American Diabetes Association; 2004.
12.
go back to reference Insulin pump therapy and continuous glucose monitoring. In: Pickup J, editor. London: Oxford University Press; 2009. Insulin pump therapy and continuous glucose monitoring. In: Pickup J, editor. London: Oxford University Press; 2009.
13.
go back to reference Kruszynska YT, Home PD, Hanning I, Alberti KGMM. Basal and 24-hour C-peptide and insulin secretion rate in normal man. Diabetologia. 1987;30:16–21.PubMedCrossRef Kruszynska YT, Home PD, Hanning I, Alberti KGMM. Basal and 24-hour C-peptide and insulin secretion rate in normal man. Diabetologia. 1987;30:16–21.PubMedCrossRef
14.
go back to reference Polonsky KS, Given BD, Van Cauter E. Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J Clin Invest. 1988;81:442–8.PubMedCentralPubMedCrossRef Polonsky KS, Given BD, Van Cauter E. Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J Clin Invest. 1988;81:442–8.PubMedCentralPubMedCrossRef
15.
go back to reference Davidson PC, Hebblewhite HR, Steed RD, Bode BW. Analysis of guidelines for basal-bolus insulin dosing: basal insulin, correction factor, and carbohydrate-to-insulin ratio. Endocr Pract. 2008;14:1095–101.PubMedCrossRef Davidson PC, Hebblewhite HR, Steed RD, Bode BW. Analysis of guidelines for basal-bolus insulin dosing: basal insulin, correction factor, and carbohydrate-to-insulin ratio. Endocr Pract. 2008;14:1095–101.PubMedCrossRef
16.
go back to reference Walsh J, Roberts R, Bailey T. Guidelines for insulin dosing in continuous subcutaneous insulin infusion using new formulas from a retrospective study of individuals with optimal glucose levels. J Diabetes Sci Technol. 2010;4:1174–81.PubMedCentralPubMedCrossRef Walsh J, Roberts R, Bailey T. Guidelines for insulin dosing in continuous subcutaneous insulin infusion using new formulas from a retrospective study of individuals with optimal glucose levels. J Diabetes Sci Technol. 2010;4:1174–81.PubMedCentralPubMedCrossRef
17.
go back to reference King AB, Armstrong DU. A prospective evaluation of insulin dosing recommendations in patients with type 1 diabetes at near normal glucose control: bolus dosing. J Diabetes Sci Technol. 2007;1:42–6.PubMedCentralPubMedCrossRef King AB, Armstrong DU. A prospective evaluation of insulin dosing recommendations in patients with type 1 diabetes at near normal glucose control: bolus dosing. J Diabetes Sci Technol. 2007;1:42–6.PubMedCentralPubMedCrossRef
18.
go back to reference Kuroda A, Kaneto H, Yasuda T, et al. Basal insulin requirement is 30 % of the total daily insulin dose in type 1 diabetic patients who use the insulin pump. Diabetes Care. 2011;34:1089–90.PubMedCentralPubMedCrossRef Kuroda A, Kaneto H, Yasuda T, et al. Basal insulin requirement is 30 % of the total daily insulin dose in type 1 diabetic patients who use the insulin pump. Diabetes Care. 2011;34:1089–90.PubMedCentralPubMedCrossRef
19.
go back to reference Kuroda A, Yasuda T, Takahara M, et al. Carbohydrate-to-insulin ratio is estimated from 300-400 divided by total daily insulin dose in type 1 diabetes patients who use the insulin pump. Diabetes Technol Ther. 2012;14:1077–80.PubMedCrossRef Kuroda A, Yasuda T, Takahara M, et al. Carbohydrate-to-insulin ratio is estimated from 300-400 divided by total daily insulin dose in type 1 diabetes patients who use the insulin pump. Diabetes Technol Ther. 2012;14:1077–80.PubMedCrossRef
20.
go back to reference King AB. Continuous glucose monitoring guided insulin dosing in pump-treated type 1 diabetes: A clinical guide. J Diabetes Sci Technol. 2012;6:191–203.PubMedCentralPubMedCrossRef King AB. Continuous glucose monitoring guided insulin dosing in pump-treated type 1 diabetes: A clinical guide. J Diabetes Sci Technol. 2012;6:191–203.PubMedCentralPubMedCrossRef
Metadata
Title
Reassessment of Insulin Dosing Guidelines in Continuous Subcutaneous Insulin Infusion Treated Type 1 Diabetes
Author
Allen Bennett King
Publication date
01-06-2014
Publisher
Springer US
Published in
Current Diabetes Reports / Issue 6/2014
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-014-0503-3

Other articles of this Issue 6/2014

Current Diabetes Reports 6/2014 Go to the issue

Pharmacologic Treatment of Type 2 Diabetes (A Vella, Section Editor)

Use of Metformin in Diseases of Aging

Pathogenesis of Type 2 Diabetes and Insulin Resistance (RM Watanabe, Section Editor)

Lipotoxicity in the Pancreatic Beta Cell: Not Just Survival and Function, but Proliferation as Well?

Macrovascular Complications in Diabetes (L Perreault, Section Editor)

Environmental Endocrine Disruption of Energy Metabolism and Cardiovascular Risk

Macrovascular Complications in Diabetes (L Perreault, Section Editor)

Cardiovascular Risk Stratification and Management in Pre-Diabetes

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.